News & Press

OET awarded Innovate UK grant for Covid-19 vaccine development

Government funding announced for Oxford biotech company to work with leading Australian vaccine company on the development of a new and innovative Covid 19 vaccine.   A grant from Innovate UK, part of UK Research and Innovation, has been made to support a partnership between Vaxine Pty Ltd  (http://vaxine.net) who developed the world’s first swine flu vaccine in 2009, and Oxford Expression Technologies (https://oetltd.com). This Innovate UK grant endorses the

SARS-CoV-2 (COVID-19 Virus) Research

OET is currently helping COVID-19 research efforts by producing the recombinant spike glycoprotein of SARS-CoV-2 for clients. The protein will be used for further research, diagnostics and potential vaccine production. OET is also engaged in in-house COVID-19 research and is working on an insect cell-based vaccine using our flashBAC system enabled through funding from Innovate UK/Department of Health through the Vaccines for Global Epidemics:development and manufacture initiative. OET has recently received further

Message to Customers

At the present time Oxford Expression Technologies remains open and is working to complete client projects and dispatch kits and products. Our timescales may be slightly delayed whilst we comply with Government restrictions and prioritise the safety and wellbeing of OET staff. We will be contacting customers to ascertain that they are able to receive goods before shipping and are pleased to report that we can now ship media to

Expression Systems Media

Expression Systems Insect Cell Culture Media OET is pleased to offer a wide range of Expression Systems Insect cell culture media, from the very popular ESF 921, to specialized insect transfection media. Expression Systems’ media are easy to adapt your cells into and the insect specific media gives great protein yield, when compared to rival media. ESF 921 Insect Culture Media OET use ESF 921 for all in-house work, due

New pOET9 Vectors!

pOET9 transfer vectors from OET incoporate baculovirus technology with unique mammalian promoters to facilitate protein production in mammalian cell lines.

baculoQUANT™ ALL-IN-ONE Titration of Recombinant Baculoviruses

There are many methods available for the titration of recombinant baculoviruses.  One of the most convenient is the use of the quantitative polymerase chain reaction (qPCR), which assesses how much virus DNA is present in a freshly-amplified stock.  This is compared with a standard curve derived from a control virus stock to give an infectious titre expressed as Q plaque forming units (pfu) per millilitre.  OET Ltd market the baculoQUANT™

OET at the European Congress of Virology 2019

The OETeam have returned after a very successful four days at the European Congress of Virology 2019 hosted in Rotterdam, the Netherlands. As one of the congress sponsors, OET’s exhibition stand proved popular among both experienced and new baculovirus researchers as well as those individuals curious for an alternative protein expression platform.  In addition, four OET scientists were each able to present a research poster, all of which can be

Impact of Brexit

As you are aware the UK is due to leave the EU. Negotiations are still ongoing so it is yet unclear how this will affect trade going in and out of the UK. OET will be preparing for all possible outcomes as best we can to ensure that customer orders can still be fulfilled. However, we recommend that if you know you will require OET products in the initial months

OET Visits Key Partners in Mexico for Diabetes Type I Research

OET scientists, Dr Mine Aksular and Dr Leo Graves, recently travelled to Mexico City to spend six days visiting the Centre for Molecular and Cell-Based Therapeutics (CMCBT) as part of an international research collaboration (TRANSDIA) investigating a novel therapy for type I diabetes. Accompanied by collaborator Dr Stephen Hughes from the Nuffield Department of Surgical Sciences, Oxford University, the team were able to provide expert advice and practical guidance on

OET Presenting at South Wilts Virus Group Annual Meeting

OET will be sponsoring and presenting at this year’s South Wilts Virus Group (SWVG) annual meeting on Thursday 24th May. The event, hosted by Oxford Brookes University Department of Biological and Medical Sciences, will allow OET scientists to exhibit our current research achievements and network with other specialists in the virology field. The SWVG is a forum for virologists in the Wiltshire/Surrey/Berkshire/ Oxfordshire region. The organisation originally began in 1952

OET is Awarded £2 Million Vaccine Development Contract

Oxford, UK – 4th May 2018   Oxford Expression Technologies Ltd (OET) is pleased to announce that it has been awarded a £2M contract from Innovate UK as part of the ‘Vaccines for Global Epidemics’ Round 2 competition. The award will allow OET to continue its ongoing work in developing the first economically viable vaccine against Crimean Congo Haemorrhagic Fever (CCHF) virus. The Vaccines for Global Epidemics competition supports the

Product Launch – pOET8!

November marks the welcome of OET’s newest product – the pOET8 baculovirus transfer vectors (pOET8.VE1; pOET8.VE2; pOET8.VE3).  Compatible with any baculovirus expression system, including our own flashBACTM technology, the new range of pOET8 vectors are proven to help increase recombinant protein production in insect cells. The increased yield is achieved by allowing co-expression of foreign genes with a vankyrin expression cassette.  This gene cassette comprises the Campoletis sonorensis ichnovirus P-vank-1 protein

flashBAC™ 5+1 offer

OET’s flashBAC™ 5 reaction kit ranges are some of our most popular products. However, recent feedback has revealed that some customers are reluctant to make use of the positive control transfer vector as this sacrifices 1 reaction and so reduces the number of their own viruses that they can produce. In recognition of this issue, until further notice, we are increasing the amount of flashBAC™ DNA in all of our

1 2